Connetics Olux adds non-scalp psoriasis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Connetics hopes to significantly expand the market for Olux (clobetasol propionate, 0.05%) with the Dec. 20 approval of the topical corticosteroid foam for short-term treatment of mild to moderate non-scalp psoriasis (excluding the face and intertriginous areas). The company estimates that approximately 80% of all prescriptions for psoriasis are for areas other than the scalp. Olux was previously approved for steroid-responsive scalp dermatose